School of Medicine
Showing 41-60 of 162 Results
-
Alan Schroeder
Clinical Professor, Pediatrics
BioDr. Schroeder is the associate chief for research in the division of pediatric hospital medicine at Lucile Packard Children’s Hospital Stanford, and a clinical professor in the division of hospital medicine and the division of critical care. His research interests focus on identifying areas where we can “safely do less” in healthcare, striving to ensure that children get the healthcare that they need while avoiding excessive tests and treatments that only cause harm. Dr. Schroeder is currently involved in multiple projects involving common conditions and interventions in pediatrics. He serves as the Stanford PI for PEDSNet and is an Associate Editor for the journal Hospital Pediatrics. At Stanford he co-leads the residency clinical research scholarly concentration and the faculty Clinical Research Peer Scholarship Community. Dr. Schroeder provides clinical care for children in the PICU and the pediatric ward.
-
Liora Schultz
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
BioI am currently postdoctoral research fellow pursuing immunotherapy research in the oncology department at Stanford University. My clinical training as a pediatric hematology oncology fellow at Memorial Sloan Kettering Cancer Center highlighted the desperate need for novel therapeutic options for a subtype of aggressive pediatric leukemia, Acute Myeloid Leukemia (AML). Despite our best standard of care for AML, long term survival rates range from 50-60% with an unacceptably high relapse rate of 40%. The urgent need for novel treatments inspired me to pursue a research project in adoptive immunotherapy, genetically modifying Tcells to express artificial T cell receptors, termed chimeric antigen receptors (CARs), that target AML specific antigens. In parallel to my clinical training, I constructed an AML specific CAR and demonstrated its ability to redirect T cell function mediating eradication of AML cells. As the field of CAR therapy rapidly advances, novel methods to optimize this therapeutic modality are imperative. To this end, supported by research demonstrating superior antitumor function of naïve derived effector T cells compared to central memory derived effector T cells, I am investigating whether preferential modification of naïve T cells to express CARs will generate a T cell subpopulation with increased efficacy. Consolidating my clinical and research experiences within highly academic institutes allows me to synthesize my pursuit of scientific rigor and commitment to the field of oncology, with a mission to achieve productive research and translatable results.
-
Jennifer Chie Schymick
Clinical Assistant Professor (Affiliated), Pediatrics - Genetics
BioPROFESSIONAL EDUCATION
∗ Medical Genetics Fellowship Stanford University (2018-2020)
∗ General Internal Medicine Residency University of Toronto (2013-2018)
∗ M.D. University of California Irvine (2009-2013)
∗ Ph.D. Oxford University & National Institutes of Health (2005-2009)
∗ B.Sc. Massachusetts Institute of Technology (1998-2002) -
Christopher Thomas Scott, PhD
Sr Research Scholar, Pediatrics - Center for Biomedical Ethics
Current Research and Scholarly InterestsMy research focuses on the political, legal, ethical and economic impacts of stem cell research. Topics include: embryonic and adult stem cell research and clinical trials, stem cell banking, human-animal chimeras; cell and gamete donation; international perspectives of bioethics; global economic impacts; national and state regulatory policy, stem cell entrepreneurship, intellectual property and offshore stem cell transplants.
-
Talal Seddik
Clinical Associate Professor, Pediatrics - Infectious Diseases
Current Research and Scholarly InterestsTalal Seddik is a member of the Collaborative Antiviral Study Group. He is the key site investigator at the Stanford site for the following multicenter studies:
1) DMID 19-0026 Enterovirus Study
Neonatal Enterovirus and Human Parechovirus Viral Sepsis: Natural History and Predictors of Morbidity and Mortality
This study will be the first large, multi-state prospective assessment of the viral causes of neonatal sepsis conducted. The main reason for this research study is to get a better understanding of what causes neonatal viral sepsis and to assess the impact of the infection on the babies’ health. Viruses called enterovirus (EV) or human parechovirus (HPeV) are very common in the population and can cause neonatal viral sepsis. By gaining a better understanding of the condition, we hope this information can be used to guide diagnosis and treatment of babies with neonatal viral sepsis in the future.
This study is actively enrolling subjects
2) DMID 19-0005 Acute Flaccid Myelitis (AFM) Study
A Prospective Study of Acute Flaccid Myelitis (AFM) to Define Natural History, Risk Factors and Pathogenetic Mechanisms
Patients with suspected AFM (onset of flaccid limb weakness within the previous 30 days) are eligible to enroll in the study. Investigators will assess participants at four-time points within the first month of enrollment and will ask participants to return for additional follow up visits at 3 months, 7 months and 1 year. Neurologic improvements will be tracked over time, and samples will be collected and stored in a biorepository for use in future research studies. Household contacts, such as siblings, will be eligible to participate in the study as a control or comparison group.
This study is actively enrolling subjects. -
Zachary M. Sellers, MD, PhD
Adjunct Professor, Pediatrics - Gastroenterology
BioDr. Sellers is a pediatric physician-scientist and research and clinical development consultant. As a pediatric gastroenterologist and ion channel physiologist, Dr. Sellers' work in academia and pharma over the last 20 years has focused on improving the lives of individuals with complex and rare diseases through providing cutting-edge clinical care and advancing research and drug development. Dr. Sellers previously led a basic and translational research laboratory at Stanford, focused on epithelial ion transport and acid-base regulation using a variety of human and animal models. He is a firm believer in the exponential impact of team science and is adept working in multi-disciplinary and cross-functional teams. He seeks out strategic partnerships and opportunities that can leverage his expertise and leadership to advance innovative therapies for areas of high unmet need and to support the development of the next generation of physician-scientists. Dr. Sellers received his BS (Animal Physiology and Neuroscience) and BA (Japanese Studies) from the University of California. San Diego, his MD and PhD (Molecular and Integrative Physiology) from the University of Illinois at Urbana-Champaign, and was trained in Pediatrics and Pediatric Gastroenterology, Hepatology, and Nutrition at Stanford, where he was previously a faculty member and attending physician. He held multiple leadership positions at Stanford, including Associate Chief of Research in Gastroenterology, Director of the Stanford Children's Pancreas Program, Lead Gastroenterologist for the CF Program, Director of the CFTR Phenotyping and Theratyping Program, and Physician-Scientist Advisor for the Pediatrics Residency Program.
-
Ami J. Shah
Clinical Professor, Pediatrics - Stem Cell Transplantation
BioI joined Stanford University in 2015 as a Clinical Professor of Pediatrics in the Division of Hematology/ Oncology, Stem Cell Transplantation and Regenerative Medicine, having completed my training in Pediatric Hematology/ Oncology at Childrens Hospital Los Angeles. My areas of clinical expertise have been in the areas of transplantation for immune deficiencies and immune reconstitution post HSCT. I have been actively involved with the care and treatment of children with primary immune deficiencies and work with the Primary Immune Deficiencies Consortium (PIDTC). I am very interested in cellular therapies as a treatment modality for rare genetic diseases. I currently am the PI for several gene therapy trials at Stanford for various disorders including cerebral adrenoleukodystrophy (cALD), Sickle Cell Anemia, Thalassemia and Pyruvate Kinase Deficiency. My other main areas of research have been in studying the late effects of patients following stem cell transplantation, in specific the neurocognitive function post HSCT. I have been involved with several national committees addressing the late effects of HSCT within the ASBMT and COG.
In addition to my research work in stem cell transplantation, I have been actively involved with mentorship and graduate medical education. I am currently the Program Director for the Hematology/ Oncology Fellowship and serve as a mentor through the Pediatric Mentoring Group. -
Mona D. Shah, MD, MBA
Adjunct Clinical Associate Professor, Pediatrics - Hematology & Oncology
BioDr. Mona Shah is a pediatric hematologist-oncologist, who earned her MD degree at the University of Maryland in 2001. She completed both her categorical pediatrics and global health residencies in 2004, followed by a pediatric hematology-oncology fellowship in 2007. She earned her MS in Clinical Investigation as part of the Clinical Scientist Training Program (CSTP) at Baylor College of Medicine in 2011, and more recently, completed an Executive MBA at Rice University Jones School of Business in 2018.
Dr. Shah was an Associate Professor at Baylor College of Medicine (2007 - 2020) in both Pediatrics and Medicine, local site PI on a number of pediatric hemostasis/thrombosis clinical trials, and spent 10 years as an Associate Medical Director of Clinical Operations, Quality, and Safety at Texas Children’s Hospital, Houston, TX.
Dr. Shah joined Genentech (a Member of the Roche Group)’s Rare Blood Disorders Franchise (Product Development - Oncology-Hematology) in February 2020, quickly advancing to Lead Medical Director, where she served as Medical Monitor for 2 Phase III Clinical Trials (crovalimab in atypical hemolytic uremic syndrome, aHUS). She was also engaged with the Renal Franchise (I2O) in developing crovalimab in Lupus Nephritis (Phase I & II Clinical Trials in development), and with Human Factors/Pediatric Formulations Working Group on autoinjector devices and oral formulations.
After completing a rotation in Early Development Safety (EDS), she was promoted to Senior Medical Safety Director in Late Stage Product Development, and was appointed Safety Strategy Lead for giredestrant in early and metastatic breast, ovarian, and endometrial cancer global clinical trials. She has experience in innovative study designs (adaptive/multi-drug), with FDA/EMA pediatric investigational plans, and health authority interactions. In June 2023, she was appointed Pediatric Safety Lead, in collaboration with the iPODD Team, supporting safety for pediatric indications and devices, and serves as the Co-Chair of the Pediatric Safety Expert Group.
Dr. Shah has kept and completed a bucket list since she was 7 years old (keeps growing): Running wild bouldering/rock climbing as a child in the Shenandoah/Blue Ridge Mountains, swimming with dolphins/piranhas in the Amazon, climbing inside a volcano caldera in Iceland, snorkeling the Great Barrier Reef ... have passport/will travel!
Since July 2022, she has joined Stanford University School of Medicine, as an Adjunct Clinical Associate Professor in the Department of Pediatrics, Division of Hematology-Oncology, where she enjoys teaching MSII students, and at the bedside in the Lucille Packard Bass Center Hematology Clinic. Dr. Shah enjoys free time in her new home base near San Francisco, where she hosts her visiting parents, friends, and extended family.
